Squamous-cell carcinomas of the lung: Emerging biology, controversies, and the promise of targeted therapy

The Lancet Oncology

Volumn 13, Issue 10, 2012, Pages

  Drilon, Alexander ^a   Rekhtman, Natasha ^a   Ladanyi, Marc ^a   Paik, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOKERATIN 5; CYTOKERATIN 6; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; IMATINIB; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NILOTINIB; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM COMPLEX; PROTEIN P63; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SOX2; UBIQUITIN PROTEIN LIGASE E3;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CARCINOGENESIS; DDR2 GENE; DRUG EFFICACY; DRUG SAFETY; FGFR1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; KEAP1 GENE; KERATINIZATION; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG SQUAMOUS CELL CARCINOMA; MORPHOLOGY; NFE2L2 GENE; NONHUMAN; ONCOGENE; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOX2 GENE; TREATMENT RESPONSE;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; GENE AMPLIFICATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MEMBRANE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, MITOGEN; RNA, MESSENGER; SOXB1 TRANSCRIPTION FACTORS;

EID: 84866865231     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70291-7     Document Type: Review

References (78)

1. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). Proc Am Soc Clin Oncol 2011, 29(suppl). abstr CRA7506.
2. Travis WD Pathology of lung cancer. Clin Chest Med 2011, 32:669-692.
3. Dodds L, Davis S, Polissar L A population-based study of lung cancer incidence trends by histologic type, 1974-81. J Natl Cancer Inst 1986, 76:21-29.
4. Janssen-Heijnen M, Nab HW, van Reek J, van der Heijden LH, Schipper R, Coebergh JW Striking changes in smoking behaviour and lung cancer incidence by histological type in south-east Netherlands, 1960-1991. Eur J Cancer 1995, 31A:949-952.
5. Funai K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 2003, 27:978-984.
6. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg 2004, 78:222-227.
7. Rusch VW Management of Pancoast tumours. Lancet Oncol 2006, 7:997-1005.
8. Travis WD, Brambilla E, Mullere-Hermelink HK, Harris CC World Health Organization classification of tumors. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon.
9. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011, 6:1849-1856.
10. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011, 24:1348-1359.
11. Travis WD, Rekhtman N Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32:22-31.
12. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012, 25:405-415.
13. Ohtsuka K, Ohnishi H, Fujiwara M, et al. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 2007, 109:741-750.
14. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011, 35:1226-1234.
15. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
16. Einhorn LH First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. J Clin Oncol 2008, 26:3485-3486.
17. Socinski M, Bondarenko IN, Karaseva NA, et al. Results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. J Clin Oncol 2010, 28:182.
18. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
19. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
20. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
21. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009, 27:1405-1412.
22. Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 2011, 6:109-114.
23. Pajares MJ, Agorreta J, Larrayoz M, et al. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 2012, 30:1129-1136.
24. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
25. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531. on behalf of the FLEX Study Team.
26. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13:33-42.
27. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63:1727-1730.
28. Wistuba II Genetics of preneoplasia: lessons from lung cancer. Curr Mol Med 2007, 7:3-14.
29. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000, 60:1949-1960.
30. Wilkerson MD, Yin X, Hoadley KA, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010, 16:4864-4875.
31. Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999, 18:643-650.
32. Leemans CR, Braakhuis BJ, Brakenhoff RH The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11:9-22.
33. Ishizumi T, McWilliams A, MacAulay C, Gazdar A, Lam S Natural history of bronchial preinvasive lesions. Cancer Metastasis Rev 2010, 29:5-14.
34. Bishop JA, Ogawa T, Chang X, et al. HPV analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. Am J Surg Pathol 2012, 36:142-148.
35. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006, 66:7466-7472.
36. Larsen JE, Pavey SJ, Passmore LH, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007, 28:760-766.
37. Inamura K, Fujiwara T, Hoshida Y, et al. Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization. Oncogene 2005, 24:7105-7113.
38. Travis W, Rekhtman N, Shen R, et al. Molecular histologic correlations in the Cancer Genome Atlas (TCGA) study of lung squamous cell carcinoma (SQC). Lab Invest 2012, 92:491A.
39. Hussenet T, du Manoir S SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle 2010, 9:1480-1486.
40. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.
41. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010, 5:e8960.
42. Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011, 24:944-953.
43. Lu Y, Futtner C, Rock JR, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One 2010, 5:e11022.
44. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000, 97:5462-5467.
45. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003, 63:7113-7121.
46. Solis LM, Behrens C, Dong W, et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010, 16:3743-3753.
47. Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006, 3:e420.
48. Shibata T, Ohta T, Tong KI, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008, 105:13568-13573.
49. Shibata T, Saito S, Kokubu A, Suzuki T, Yamamoto M, Hirohashi S Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res 2010, 70:9095-9105.
50. Kim YR, Oh JE, Kim MS, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010, 220:446-451.
51. Sarkaria I, O-charoenrat P, Talbot SG, et al. Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. Cancer Res 2006, 66:9437-9444.
52. O-charoenrat P, Sarkaria I, Talbot SG, et al. SCCRO (DCUN1D1) induces extracellular matrix invasion by activating matrix metalloproteinase 2. Clin Cancer Res 2008, 14:6780-6789.
53. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
54. Chaft JE, Rekhtman N, Ladanyi M, Riely GJ ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol 2012, 7:768-769.
55. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18:1167-1176.
56. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
57. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006, 103:7817-7822.
58. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, Fujii Y EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep 2007, 17:319-323.
59. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54:209-215.
60. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68:6913-6921.
61. Okudela K, Suzuki M, Kageyama S, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007, 57:664-671.
62. Ji M, Guan H, Gao C, Shi B, Hou P Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011, 11:147.
63. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008, 1:14.
64. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008, 7:665-669.
65. Jin G, Kim MJ, Jeon HS, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010, 69:279-283.
66. Do H, Salemi R, Murone C, Mitchell PL, Dobrovic A Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung. Cell Cycle 2010, 9:4411-4412.
67. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002, 8:1178-1184.
68. Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012, 11:485-491.
69. Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002, 62:5210-5217.
70. Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol 2009, 4:578-585.
71. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2:62ra93.
72. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011, 6:e20351.
73. Turner N, Grose R Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
74. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel WF Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br J Cancer 2007, 96:808-814.
75. Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
76. Hammerman P, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1:78-89.
77. Day E, Waters B, Spiegel K, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599:44-53.
78. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, The Cancer Genome Atlas Research Network, published online Sept 9. 10.1038/nature11404.